<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940513-2-00111</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> No change. The Office of Drug Pricing has currently developed a proposed dispute resolution process which will be published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> with a public comment period. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Require PHS preclearance of all safeguard systems developed by entities to deter diversion and require this information to be supplied to the manufacturers upon request. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> No change. Guidelines concerning separate purchasing accounts and dispensing records are quite specific, and procedures in these areas need no prior approval. If a manufacturer believes that a covered entity is involved in drug diversion, it has the statutory authority to audit the entity records that directly relate to drugs of that manufacturer purchased at PHS pricing. Proposed audit guidelines have been developed and will be published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> with a public comment period. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Issue criteria for measuring the adequacy of the safeguards. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> No change. If a manufacturer believes that a covered entity has established inadequate safeguards and is involved in drug diversion, then the manufacturer can either audit the entity or file a complaint with the Office of Drug Pricing. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Develop a broad definition of ``patient'' to include all necessary services provided to individuals served by the covered entities. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> No change. The notice does not address the definition of patient. The Office of Drug Pricing is in the process of developing a definition of patient, which will be published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Public comment will be invited, and this comment will be considered at that time. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Do not require separate inventories, as this would place a hardship on most hospitals. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> No change. There is no requirement for separate inventories. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Do not permit entities to develop alternate tracking systems or develop criteria for these systems by March 1, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> No change. It is essential that the Office of Drug pricing maintain some flexibility during this period of implementation. Because these alternate tracking systems require prior approval from the Office of Drug pricing before they can be implemented, sufficient control is maintained. The Office will develop criteria at a later date and welcomes all suggestions. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> Audit Requirements <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Specify the statutory basis for the Secretary to authorize manufacturer audit guidelines. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Response:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> We have amended part 5 of the notice to include a reference to section 340B(a)(5)(C) of the PHS Act, which gives the Secretary the authority to establish procedures relating to the number, duration, and scope of manufacturer audits. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comment:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Move quickly to develop procedures to allow manufacturers to audit records of entities' purchases of covered outpatient drugs and of Medicaid claims for reimbursement for such drugs. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            